Background: High-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglyceride concentrations are heritable risk factors for vascular disease, but their role in the progression of chronic kidney disease (CKD) is unclear.
Study design: 2-sample Mendelian randomization analysis of data derived from the largest published lipid and CKD studies.
Setting & participants: Effect of independent genetic variants significantly associated with lipid concentrations was obtained from the Global Lipids Genetics Consortium (n=188,577), and the effect of these same variants on estimated glomerular filtration rate (eGFR), CKD (defined as eGFR<60mL/min/1.73m2), and albuminuria was obtained from the CKD Genetics Consortium (n=133,814).
Factor: Using conventional, multivariable, and Egger Mendelian randomization approaches, we assessed the causal association between genetically determined lipid concentrations and kidney traits.
Outcome: eGFR, dichotomous eGFR<60mL/min/1.73m2, and albuminuria.
Results: In multivariable analysis, a 17-mg/dL higher HDL cholesterol concentration was associated with an 0.8% higher eGFR (95% CI, 0.4%-1.3%; P=0.004) and lower risk for eGFR<60mL/min/1.73m2 (OR, 0.85; 95% CI, 0.77-0.93; P<0.001), while Egger analysis showed no evidence of pleiotropy. There was no evidence for a causal relationship between LDL cholesterol concentration and any kidney disease measure. Genetically higher triglyceride concentrations appeared associated with higher eGFRs, but this finding was driven by a single pleiotropic variant in the glucokinase regulator gene (GCKR). After exclusion, genetically higher triglyceride concentration was not associated with any kidney trait.
Limitations: Individual patient-level phenotype and genotype information were unavailable.
Conclusions: 2-sample Mendelian randomization analysis of data from the largest lipid and CKD cohorts supports genetically higher HDL cholesterol concentration as causally associated with better kidney function. There was no association between genetically altered LDL cholesterol or triglyceride concentration and kidney function. Further analysis of CKD outcomes in HDL cholesterol intervention trials is warranted.
Keywords: Lipid metabolism; Mendelian randomization; chronic kidney disease (CKD); dyslipidemia; genetics; high-density lipoprotein (HDL) cholesterol; kidney disease progression; low-density lipoprotein (LDL) cholesterol; modifiable risk factors; renal disease; triglycerides.
Copyright © 2017 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.